Arkolith/Insider Trading/TNGX/Form 4

Crystal Adam

President, R&DTango Therapeutics, Inc. (TNGX) · full profile →Form 4 · filed Apr 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$572K
Net Open-Market Flow
-$572K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)27K$5.20$140K140K
Apr 1, 2026Sell(S)27K$21.20$572K113K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)27K—$0434K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-140874) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML